// App-Quantinova.ai

e16074 : Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.

Researchers

Presenter

  • Quoc Dang Vu

Principal Investigators

  • Katharina von Loga

  • Shan E Ahmed Raza

  • Daniel Nava Rodrigues

  • Bijal Patel

  • Clare Peckitt

  • Ruwaida Begum

  • Avani Athauda

  • Naureen Starling

  • Ian Chau

  • Sheela Rao

  • David J. Watkins

  • Marlon Rebelatto

  • Tom Waddell

  • Jonathan Wadsley

  • Tom Roques

  • Madeleine Hewish

  • David Cunningham

  • Nasir Rajpoot

Medical Centers

  • University of Warwick, Coventry, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • AstraZeneca, Gaithersburg, MD, The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Weston Park Hospital, Sheffield, United Kingdom

  • Paediatrics, Norfolk and Norwich University Hospitals NHS Foundation Trust,Norwich, United Kingdom

  • Royal Surrey County Hospital, Guildford, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • NCT02678182

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved